NYSE$MD
Pediatrix Medical Group, Inc. · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported a loss from continuing operations due to the impact of COVID-19 and sale of American Anesthesiology.
MEDNAX reported a challenging first quarter, marked by a net revenue of $846 million but a loss of $16 million. The company's performance was significantly impacted by the COVID-19 pandemic, which reduced consolidated revenue by approximately $40 million compared to forecasted revenue. Additionally, MEDNAX completed the sale of American Anesthesiology subsequent to the end of the quarter.
- Net revenue for the quarter was $846 million.
- Loss from continuing operations was $16 million, or $0.20 per share.
- Adjusted EPS from continuing operations was $0.32.
- Adjusted EBITDA from continuing operations was $63 million.
Headline financials
Revenue & EPS history
Pediatrix · Revenue · Quarterly
$846M
Forward guidance
Due to the rapidly evolving environment and continued uncertainties surrounding the impact of COVID-19, the Company is not providing any outlook for its performance for the second quarter of 2020 or for the full year 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+0.4%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
34 / 68 earnings
Positive
+31.3%
Q3 2020
Best reaction
-24.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -7.3% | +5.2% | +0.0% | |
| Q4 2025 | -12.2% | -8.7% | -10.3% | |
| Q3 2025 | +21.3% | +29.2% | +37.2% | |
| Q1 2025 | +12.1% | +12.2% | +7.5% | |
| Q4 2024 | +22.1% | +9.1% | +0.7% | |
| Q3 2024 | +22.9% | +30.5% | +21.4% | |
| Q2 2024 | +26.4% | +31.5% | +40.9% | |
| Q1 2024 | -8.4% | -11.4% | -25.8% | |
| Q4 2023 | -6.8% | -5.4% | +0.6% | |
| Q3 2023 | -11.7% | -11.8% | -21.8% | |
| Q2 2023 | +5.9% | +6.4% | +1.2% | |
| Q1 2023 | -2.4% | -4.5% | -5.4% | |
| Q4 2022 | +4.6% | +5.8% | -5.0% | |
| Q3 2022 | -16.2% | -18.3% | -12.6% | |
| Q2 2022 | -12.1% | -7.8% | -22.1% | |
| Q1 2022 | -18.5% | -16.6% | -14.4% | |
| Q4 2021 | -9.2% | -8.9% | -6.9% | |
| Q3 2021 | -1.2% | -3.3% | -10.7% | |
| Q2 2021 | +7.9% | +11.4% | +2.1% | |
| Q1 2021 | +19.5% | +14.8% | +19.4% | |
| Q4 2020 | -20.5% | -16.8% | -0.9% | |
| Q3 2020 | +31.3% | +32.0% | +60.5% | |
| Q2 2020 | -1.3% | -1.3% | -4.6% | |
| Q1 2020 | +5.6% | -0.7% | +38.7% | |
| Q4 2019 | -24.8% | -30.0% | -64.6% | |
| Q3 2019 | +14.6% | +18.1% | +18.9% | |
| Q2 2019 | -9.1% | -13.6% | -14.2% | |
| Q1 2019 | +3.8% | +3.8% | -12.7% | |
| Q4 2018 | -4.2% | -5.9% | -18.3% | |
| Q3 2018 | -5.0% | -4.4% | -2.6% | |
| Q2 2018 | +10.1% | +13.3% | +10.4% | |
| Q1 2018 | -4.4% | -3.6% | -1.4% | |
| Q4 2017 | +6.6% | +6.7% | +13.8% | |
| Q3 2017 | -4.9% | +0.1% | +15.6% | |
| Q2 2017 | -16.8% | -20.4% | -21.7% | |
| Q1 2017 | -8.5% | -9.9% | -8.2% | |
| Q4 2016 | -3.5% | -1.3% | +1.1% | |
| Q3 2016 | -6.3% | -6.3% | +1.3% | |
| Q2 2016 | -8.5% | -10.8% | -16.7% | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | +4.2% | — | — | |
| Q1 2015 | -1.2% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | +10.2% | — | — | |
| Q2 2014 | -4.5% | — | — | |
| Q1 2014 | -2.4% | — | — | |
| Q4 2013 | +5.0% | — | — | |
| Q3 2013 | +2.4% | — | — | |
| Q2 2013 | +1.4% | — | — | |
| Q1 2013 | -1.1% | — | — | |
| Q4 2012 | +0.9% | — | — | |
| Q3 2012 | +7.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | -6.6% | — | — | |
| Q4 2011 | -1.7% | — | — | |
| Q3 2011 | +2.8% | — | — | |
| Q2 2011 | -0.9% | — | — | |
| Q1 2010 | +1.8% | — | — | |
| Q1 2011 | +4.5% | — | — | |
| Q4 2010 | +2.2% | — | — | |
| Q4 2008 | +2.2% | — | — | |
| Q3 2009 | +2.0% | — | — | |
| Q3 2010 | +2.0% | — | — | |
| Q2 2010 | +2.3% | — | — | |
| Q4 2009 | +2.3% | — | — | |
| Q2 2009 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro